244 related articles for article (PubMed ID: 12133288)
21. Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice.
Greer JM; Kuchroo VK; Sobel RA; Lees MB
J Immunol; 1992 Aug; 149(3):783-8. PubMed ID: 1378866
[TBL] [Abstract][Full Text] [Related]
22. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression.
Imler TJ; Petro TM
Int Immunopharmacol; 2009 Jan; 9(1):134-43. PubMed ID: 19022403
[TBL] [Abstract][Full Text] [Related]
23. Prevention of murine EAE by oral hydrolytic enzyme treatment.
Targoni OS; Tary-Lehmann M; Lehmann PV
J Autoimmun; 1999 May; 12(3):191-8. PubMed ID: 10222028
[TBL] [Abstract][Full Text] [Related]
24. Endogenous CD4+BV8S2- T cells from TG BV8S2+ donors confer complete protection against spontaneous experimental encephalomyelitis (Sp-EAE) in TCR transgenic, RAG-/- mice.
Matejuk A; Buenafe AC; Dwyer J; Ito A; Silverman M; Zamora A; Subramanian S; Vandenbark AA; Offner H
J Neurosci Res; 2003 Jan; 71(1):89-103. PubMed ID: 12478617
[TBL] [Abstract][Full Text] [Related]
25. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice.
Amor S; Groome N; Linington C; Morris MM; Dornmair K; Gardinier MV; Matthieu JM; Baker D
J Immunol; 1994 Nov; 153(10):4349-56. PubMed ID: 7525700
[TBL] [Abstract][Full Text] [Related]
26. Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.
Kobayashi N; Kobayashi H; Gu L; Malefyt T; Siahaan TJ
J Pharmacol Exp Ther; 2007 Aug; 322(2):879-86. PubMed ID: 17522343
[TBL] [Abstract][Full Text] [Related]
27. Modulation of CD4 co-receptor limits spontaneous autoimmunity when high-affinity transgenic TCR specific for self-antigen is expressed on a genetically resistant background.
Illés Z; Waldner H; Reddy J; Anderson AC; Sobel RA; Kuchroo VK
Int Immunol; 2007 Oct; 19(10):1235-48. PubMed ID: 17804690
[TBL] [Abstract][Full Text] [Related]
28. Humoral immune recognition of proteolipid protein (PLP)-specific encephalitogenic epitopes in the SJL/J mouse.
Potter NT; Stephens TS
J Neurosci Res; 1994 Jan; 37(1):15-22. PubMed ID: 7511703
[TBL] [Abstract][Full Text] [Related]
29. Soluble mannosylated myelin peptide inhibits the encephalitogenicity of autoreactive T cells during experimental autoimmune encephalomyelitis.
Kel J; Oldenampsen J; Luca M; Drijfhout JW; Koning F; Nagelkerken L
Am J Pathol; 2007 Jan; 170(1):272-80. PubMed ID: 17200200
[TBL] [Abstract][Full Text] [Related]
30. An organic CD4 inhibitor reduces the clinical and pathological symptoms of acute experimental allergic encephalomyelitis.
Edling AE; Choksi S; Huang Z; Korngold R
J Autoimmun; 2002 Mar; 18(2):169-79. PubMed ID: 11908949
[TBL] [Abstract][Full Text] [Related]
31. A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4+ T cell responses in experimental allergic encephalomyelitis.
Marini JC; Jameson BA; Lublin FD; Korngold R
J Immunol; 1996 Oct; 157(8):3706-15. PubMed ID: 8871674
[TBL] [Abstract][Full Text] [Related]
32. The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice.
Hofstetter HH; Karulin AY; Forsthuber TG; Ott PA; Tary-Lehmann M; Lehmann PV
J Neuroimmunol; 2005 Dec; 170(1-2):105-14. PubMed ID: 16257061
[TBL] [Abstract][Full Text] [Related]
33. IL-12/IFN-gamma/NO axis plays critical role in development of Th1-mediated experimental autoimmune encephalomyelitis.
Xiao BG; Ma CG; Xu LY; Link H; Lu CZ
Mol Immunol; 2008 Feb; 45(4):1191-6. PubMed ID: 17697713
[TBL] [Abstract][Full Text] [Related]
34. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis.
Kuchroo VK; Martin CA; Greer JM; Ju ST; Sobel RA; Dorf ME
J Immunol; 1993 Oct; 151(8):4371-82. PubMed ID: 7691946
[TBL] [Abstract][Full Text] [Related]
35. A chimeric TCR-beta chain confers increased susceptibility to EAE.
Petersen TR; Lata R; Spittle E; Bäckström BT
Mol Immunol; 2007 Jul; 44(14):3473-81. PubMed ID: 17481734
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis.
Xu W; Fazekas G; Hara H; Tabira T
J Neuroimmunol; 2005 Jun; 163(1-2):24-30. PubMed ID: 15885305
[TBL] [Abstract][Full Text] [Related]
37. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
Skundric DS; Dai R; Zakarian VL; Bessert D; Skoff RP; Cruikshank WW; Kurjakovic Z
J Neurosci Res; 2005 Mar; 79(5):680-93. PubMed ID: 15682385
[TBL] [Abstract][Full Text] [Related]
38. Characterization of experimental allergic encephalomyelitis-susceptible, Biozzi AB/H (H-2dq1) mice which express H-2Anod: analysis of T-cell receptor expression and the detection of a deletion ligand encoded by Mtv-7.
Fairchild S; Baker D; Turk JL
Immunology; 1993 Feb; 78(2):260-5. PubMed ID: 8386133
[TBL] [Abstract][Full Text] [Related]
39. The immunopathology of chronic experimental allergic encephalomyelitis induced in rabbits with bovine proteolipid protein.
Sobel RA; van der Veen RC; Lees MB
J Immunol; 1986 Jan; 136(1):157-63. PubMed ID: 2415615
[TBL] [Abstract][Full Text] [Related]
40. Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein.
Greer JM; Sobel RA; Sette A; Southwood S; Lees MB; Kuchroo VK
J Immunol; 1996 Jan; 156(1):371-9. PubMed ID: 8598487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
